We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Merck Says Late-Stage Vorapaxar Study Halted Over Bleeding Risk
Merck Says Late-Stage Vorapaxar Study Halted Over Bleeding Risk
January 21, 2011
Merck confirmed Wednesday it halted one Phase III trial of its investigational blood-thinner vorapaxar and limited the patient population of another due to an increased bleeding risk in a specific patient population.